Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis
- 18 April 2013
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 35 (3) , 463-468
Abstract
Background Some publications have shown that equivalent doses of erythropoiesis-stimulating agents (ESA) defined on label differ from those effective in clinical practice. Therefore, real costs could vary from theoretical costs in the treatment of anaemia in chronic kidney disease (CKD). Objectives To perform a cost-minimization analysis to establish the economic impact of the principal ESAs used in treating anaemia secondary to CKD in daily practice. Secondary objectives: to determine patient-month cost based on the erythropoietin resistance index (ERI); to analyze the difference in cost between pre-dialysis and peritoneal dialysis (PD) patients; and to analyze the association between iron deposits and ESA cost. Setting This study was carried out at 2 tertiary hospitals in Spain. Method A multicentre cost-minimization analysis was performed in adult outpatients treated with ESAs for anaemia due to CKD. Main outcome measure The primary outcome was the patient-month cost for each ESA. Results 409 patients were included. Median patient-month cost was: epoetin (103.2 [63.7, 187.8] euros), darbepoetin α (134.4 [67.2, 216.0] euros) and CERA (147.5 [98.3, 196.7] euros). Median patient-month cost according to ERI was: epoetin (1.60 [0.90, 2.60] euros/kg), darbepoetin α (2.01 [0.95, 3.48] euros/kg) and CERA (1.87 [1.33, 3.00] euros/kg). Median patient-month cost in pre-dialysis was 126.0 (73.7, 201.6) euros and in PD 153.0 (100.2, 275.4) euros. Median patient-month cost for patients with TSI < 20 % was 147.5 (98.3, 224.9) euros compared to 100.9 (67.2, 196.7) euros which was the cost for patients with IST ≥ 20 %. The median patient-month cost for patients with ferritin < 100 mcg/l was 134.4 (85.0, 201.6) euros compared to 100.8 (68.8, 196.7) euros, which was the cost for patients with ferritin ≥ 100 mcg/l (p = 0.242). Conclusion Doses of CERA used in clinical practice are lower than those recommended on label, which directly influences cost and treatment efficiency. Cost stratification based on iron deposits has shown that patients with low TSI or ferritin require higher doses and consequently an associated higher cost. Thus, to guarantee adequate iron levels is essential in the rational use of ESAs.Keywords
This publication has 17 references indexed in Scilit:
- Conversion of Darbepoetin to Low Doses of CERA Maintains Hemoglobin Levels in Non-Dialysis Chronic Kidney Disease PatientsBlood Purification, 2010
- Análisis probabilístico de minimización de costes de darbepoetin alfa frente a epoetina alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica. Valoración en la práctica clínica españolaFarmacia Hospitalaria, 2009
- Prevalence of chronic kidney disease in population-based studies: Systematic reviewBMC Public Health, 2008
- Change in Darbepoetin Alfa Administration Schedule Affects Erythropoiesis-Stimulating Agent Resistance in Patients with Chronic Kidney Disease Receiving HemodialysisRenal Failure, 2008
- Relevance of Cost-effectiveness Analysis to Clinicians and Policy MakersJAMA, 2007
- Epidemiology of chronic renal disease in the Galician population: Results of the pilot Spanish EPIRCE studyKidney International, 2005
- Estudio Coste-Eficacia de dos Estimulantes Eritropoyéticos para el Tratamiento de la Anemia en Pacientes con Insuficiencia Renal Crónica en Hemodiálisis: Epoetinum Alfa y Darbepoetina AlfaRevista de la Sociedad Española de Enfermería Nefrológica, 2004
- Clinical and economic comparison of epoetin alfa and darbepoetin alfaCurrent Medical Research and Opinion, 2004
- Association of Kidney Function With AnemiaArchives of internal medicine (1960), 2002
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986